Novocure announced the reimbursement and availability of Optune together with temozolomide, or TMZ, for the treatment of adult patients with newly diagnosed glioblastoma, or GBM, in France. The order registering Optune on the List of Reimbursable Products and Services, or LPPR, provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28 and will become effective March 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVCR: